阿杜那单抗治疗与未治疗阿尔茨海默病的神经病理改变及淀粉样蛋白相关影像异常
该回顾性病例对照研究纳入5例经阿杜那单抗治疗的阿尔茨海默病患者尸检资料,并与12例未治疗者按遗传背景、起病年龄和性别匹配。结果显示治疗组皮质第I层Aβaa1-8与Aβ42清除,而深层皮质无明显清除;MRI对应ARIA区域可见微梗死伴含铁血黄素沉积、补体激活及CD68阳性血管壁。
要点
- 阿杜那单抗相关Aβ清除主要局限于皮质浅层,深层皮质无明显清除。
- ARIA对应区域可见微梗死、含铁血黄素沉积、补体激活及CD68阳性血管壁。
- 治疗组全部出现认知下降,2例发生ARIA,需关注靶点结合与监测。
核心结论
- 阿杜那单抗对Aβ的清除在皮质浅层呈不成比例分布,ARIA相关神经病理亦定位于浅层皮质,提示其独特的靶点结合模式。
研究设计与样本
- 回顾性病例对照研究,纳入Mayo Clinic临床试验中5例经阿杜那单抗治疗并接受尸检者,按常染色体显性AD突变或APOE基因型、认知症状起病年龄和性别匹配12例未治疗者。
主要发现
- 治疗组5例中4男1女,均携带至少一个APOE ∊4等位基因,2例携带PSEN1突变;阿杜那单抗累积剂量5 mg/kg至241 mg/kg;治疗期间全部认知下降,2例出现ARIA。
- [18F]florbetapir PET Centiloid值较基线下降范围为-6%至-81%;治疗至死亡间隔5至41个月。
- 神经病理显示治疗组皮质第I层Aβaa1-8与Aβ42清除,深层皮质无显著清除;MRI对应ARIA区域可见微梗死伴含铁血黄素、补体激活及CD68阳性血管壁,源自载Aβ的软脑膜及穿支血管。
临床怎么用
- 对接受Aβ靶向治疗的患者,应结合PET与神经病理理解Aβ清除的浅层局限性及ARIA的血管性病理基础,加强影像监测。
局限性
- 样本量小(治疗组5例),为回顾性设计,累积剂量与治疗至死亡间隔跨度大,结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding the neuropathological effects of amyloid β (Aβ)-targeting therapies and amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease is critical for optimising treatment efficacy and patient outcomes. Comparing Aβ PET imaging with neuropathological assessments provides context for evaluating the extent of Aβ clearance and interpreting in-vivo biomarkers. We aimed to assess clinicopathological changes and ARIA-related effects in aducanumab-treated versus untreated Alzheimer's disease. METHODS: This retrospective case-control study included five aducanumab-treated participants from clinical trials conducted at the Mayo Clinic (2016-21) who underwent autopsy (2020-23). Treated participants were matched by autosomal dominant Alzheimer's disease mutation or APOE genotype, age at cognitive symptom onset, and sex to 12 untreated participants from the Mayo Clinic Alzheimer's Disease Research Center and Mayo Clinic Study of Aging cohorts in the Mayo Clinic brain bank (Jacksonville, FL, USA). Cognitive, imaging, and neuropathological outcomes were compared using descriptive analyses and Mann-Whitney U tests. FINDINGS: Aducanumab-treated participants comprised four males and one female, all carrying at least one APOE ∊4 allele, with two harbouring a PSEN1 mutation. Cumulative dosages of aducanumab ranged from 5 mg/kg to 241 mg/kg; all participants cognitively declined during treatment, and two exhibited ARIA. Reductions in [18F]florbetapir PET Centiloid values ranged from -6% to -81% compared with baseline. Treatment-to-death intervals ranged from 5 months to 41 months. Neuropathological analyses revealed clearance of Aβaa1-8 and Aβ42 localised to cortical layer I in treated participants, with no significant clearance in deeper cortical layers. Regions corresponding to ARIA on MRI showed microinfarcts with haemosiderin, complement activation, and CD68-positive vessel walls originating from Aβ-laden leptomeningeal and penetrating vessels. INTERPRETATION: Disproportionate Aβ clearance and ARIA-associated neuropathology localised to superficial cortical layers suggest a distinctive pattern of target engagement by aducanumab. These findings inform understanding and monitoring of similar Aβ-targeting therapies. FUNDING: Alzheimer Nederland, National Institute on Aging, and Alzheimer's Association.
引用
- Boon BDC, Piura YD, Moloney CM, et al. Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study. Lancet Neurol. 2025. PMID: 41109234. doi:10.1016/S1474-4422(25)00313-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。